More companies need to set diversity enrollment goals in cancer trials, FDA says

The FDA re­leased draft guid­ance back in April 2022 rec­om­mend­ing that bio­phar­ma spon­sors vol­un­tar­i­ly sub­mit plans to ex­plain how they plan to en­roll their piv­otal tri­als with racial­ly and eth­ni­cal­ly rep­re­sen­ta­tive pop­u­la­tions.

Ac­cord­ing to a slide deck re­leased Tues­day by the FDA’s On­col­o­gy Cen­ter of Ex­cel­lence, about half of the plans from drug­mak­ers re­ceived feed­back from the FDA on what else they need to in­clude.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.